Eric Benevich - Aug 16, 2021 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Commercial Officer
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Stock symbol
NBIX
Transactions as of
Aug 16, 2021
Transactions value $
-$504,395
Form type
4
Date filed
8/18/2021, 06:18 PM
Previous filing
May 11, 2023
Next filing
Feb 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Sale -$504K -5.63K -26.5% $89.62 15.6K Aug 16, 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F2 Includes 137 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 26, 2021.